


EGYPTIAN COMPANY FOR BIOLOGICAL & PHARMACEUTICAL



VACCINE
VALLEY

Company Profile



VACCINE
VALLEY



Company Profile

TABLE OF CONTENT



About Vaccine Valley.	03
Vaccine Valley Core Competences.	04
Vaccine Valley Share Holders and Top Management.	09
Vaccine Valley Achievements.	18
Vaccine Valley Presence.	20
Vaccine Valley Existing Range VALLEYVAC® Xceed 0.2 ml Range.	22
Vaccine Valley Existing Range VALLEYVAC® 0.5 ml range.	26
Vaccine Valley Duck Vaccines VALLEYVAC® Duck vaccine range.	40
Vaccine Valley Soon pipeline ranges.	43
Vaccine Valley Contacts.	48



About Vaccine Valley

Vaccine valley was established in 2006 by Prof. Dr. ElSayed Badawy, Eng. AbdElSalam Hegazy & Eng. Mohsen Badawy as a dedicated facility for the production of different types of veterinary vaccines.

The Factory is located in 101 extension of the 6th industrial zone, 6th of October city, Egypt.

We aim to fulfill to the markets of the Middle East, Africa, and other countries high quality veterinary vaccines products that comply with the International Quality Standards.

Vaccine Valley collaborated with national and international scientists and researchers in the development of the units of inactivated, live and recombinant vaccines.



Vaccine Valley

Core competences



VISION

To be recognized as the leading producer of biological products in Egypt, Middle East and Africa that livestock market led by:

- Innovation
- Technology
- Benchmarking international quality standards



MISSION

Developing biological innovative products exploiting our technical and science-based expertise together with:

- State of art facility
- Adding value to our customers
- Optimizing the economic statusof the industry



Values

1

Science Based Working



Working to build up a customized portfolio with clinical trials and documented field experience through our Animal health expertise



2

Premium Quality Products

Through application of European quality standards, European ISO and Egyptian Drug Association GMP certificates. CHALLENGE test for each produced batch in lab animals house to ensure safety and efficacy Premium quality product storage and handling - Monitoring field results

3

Innovation


Through unique vaccines formula empowered by Optimum Concentrations, Balanced formula to get maximum efficacy, Unique Adjuvant and Immune stimulators added to the formula for achieving rapid and maximum level of protection.



4

Excellence in manufacturing

Through OIE standard operation procedures and premium quality raw materials as SPF Eggs used in egg based vaccines manufacture, Complete sterile production area ,and accurate mixing of balanced antigens for achieving high and balanced protection in field.



5

Bright Future

Solid vision for the coming 5 years with huge pipeline solutions will keep utilizing Science to help in solving the disease related problems of the animal health industry.





Our Customers Commitment

1

Delivering Quality

Offering high quality products To meet the poultry & Livestock industry demands that have international standards of quality.

2

Customer Satisfaction

We provide customized customer service and build the unconditional trust of our customers.

3

Social responsibility

Giving back to the community through raising awareness to small scale producers which will contribute in animal health development animal health quality of life.

4

Technology

We will continue to provide top quality products manufactured with technology and special know-how.

5

Customization

We provide customized programs fit to local demand and epidemiological situation.

Vaccine Valley

Sharholder & Top Managment

Vaccine Valley Sharholder

SHAREHOLDERS



**Prof. Dr. El sayed
Badawy**

Chairman of The Egyptian co for biological and pharmaceutical industries "Vaccine Valley" till 2021

Professor and former head of Animal and Poultry Hygiene at Faculty of veterinary medicine, Cairo University.

Technical consultant for various poultry companies.


Technical Middle East consultant of COBB breeding company from 1985 to 1999.

FAO consultant since 2006 to 2021.

Member in many local and international poultry and veterinary associations.

Chairman of El Badawy poultry company till 2021

Chairman of Biolink Egypt for chemical industries till 2021.



**Eng. AbdelSalam
Hegazy**

Founder & Board member at The Egyptian company for biological & pharmaceutical industries "Vaccine Valley"

One of the main providers of broilers parents and broiler chicks in the Egyptian market and the biggest company for supplying layer chicks in Egypt.

Responsible for almost 85% of turnkey projects of hatcheries in Egypt Agent of the world leaders in poultry and poultry equipment's (COBB VANTRESS – HENDRIX- PETERSIME- SALMET – VENCO-MATIC – VISCON – KOHLHOFF – LAGAFORS).

One of the suppliers of heavy equipment and generators to facilitate work environments for businesses (Cummings – Berkinz – Bawoo – Lovol).

Provider of high-quality consumer products (fresh chilled chicken and chicken parts- eggs -cold cuts – fresh fruits and vegetables olive oil and olives).



Eng. Mohsen Badawy

Chairman and main shareholder of The Egyptian co for biological and pharmaceutical industries "Vaccine Valley"

Worked in the main military signal workshop for maintenance and calibration of electronic equipment (1977-1988).
Performed training in Hewlett-Packard Company, Lyon France (1982).

Accomplished training in Gratic Company, Zurich Switzerland (1983)
Performed training in Fluck company, Netherlands (1985)
Executed training in Heathkit company, Chicago USA (1987)

Accomplished training in Schlumberger company, California USA (1988)
Performed on job training in GTE Corporation, Boston USA (1988-1990)

Worked in the main military signal workshop Automatic test equipment (1991-2001)

Chairman and main shareholder of El Badawy poultry company (2001-present)

Chairman and shareholder of EFM for trading (2014 -present)

Vaccine Valley Top Management

TOP MANAGEMENT



Eng. Ahmed Badawy

CEO & Board Member

CEO & Board member at The Egyptian Company for biological and pharmaceutical industries "Vaccine Valley"

Business Partner at El Badawy Poultry Company.

Founder and Managing Director of El Badawy Warehouses logistics hub.

Supervisor of construction Works at The Egyptian co for biological and pharmaceutical industries Vaccine Valley.

CEO & Board member at Biolink Egypt for Chemical industries.



Dr. Mohamed Adel

Commercial Director

Since 1st of July 2020 Dr. Mohamed Adel joined forces with Vaccine Valley as the Commercial General Manager.

Dr. Adel is responsible for formulating and implementing the overall strategy to bring the company to the next level.

Prior to Vaccine Valley he spent more than 15 years holding several positions in sales, marketing and general management at both human and veterinarian multinational pharmaceuticals across Middle East and Africa region.

His career comes in a lot of success in building the right team capabilities to bridge the gaps and provide excellence in customer experience.

He is a high honors graduate of pharmacy and holds an Executive MBA from IESE business school in 2010.



**Dr. Vinayak
R. Brahmakshatriya**

Research and Development Director

Dr. Brahmakshatriya V, received his bachelor degree in Veterinary medicine at Maharashtra Animal & Fishery Science University, India, and master's degree in Poultry disease research and diagnosis at University of Delaware, Newark, DE, USA.

He was awarded a Ph.D.'s degree in Molecular Virology at Texas A&M University, College Station, TX, US.

In USA, he held the position of Graduate Research Assistant, Laboratory of Dr. Rosenberger, University of Delaware, Newark, DE. He moved to Laboratory of Dr. Reddy, Texas A & M University, College Station, TX as a Graduate Research Assistant to study more about immunopathogenesis the immune response and its application in vaccine design using recombinant DNA technology and Reverse genetics. He became a Postdoctoral Fellow at Trudeau Institute, Saranac Lake, NY and UMass Medical School, Worcester, MA, for working on understanding the role of TLR treated dendritic cell on immune response.

Finally, he held the position of Scientist, Vaccine Research Head, Ventri Biologicals, Pune, India, developing recombinant and subunits vaccines.

He is currently the Research and Development Director for the Egyptian Company for Biological and Pharmaceutical Industries (Vaccine Valley).

Achievements



ISO 9001: 2015

Quality Management System



ISO 45001

Standards for management system of occupational health and safety



ISO 14001


Quality Management System dealing with the process of how a service or product is delivered, produced, rather than to the product or service quality it self

"Vaccine Valley ISO certificates are European to meet premium international quality standards requirement in production and manufacturing."



GMP


Egyptian Drug Association Good Manufacturing Practice "GMP" Certificate
To be the 1st biological products manufacturer able to produce both animal health and human being biological products



ISO/IEC 17025:2017 Quality Control Laboratories

Vaccine Valley

Presence



Vaccine Valley is currently present in 20 countries, as shown on the map. Our objective for 2030 is to achieve a global presence.

 **Headquarter**

 **Agents**





Vaccine Valley

Existing Range

VALLEYVAC[®] Xceed 0.2 ml Range

VALLEYVAC® Xceed H9-ND^{G7}

The unique inactivated H9-ND^{G7} vaccine especially designed for broiler flocks with full high concentration in 0.2 dose and empowered by immune stimulating complex for wide, rapid and high level of protection for broiler flocks against Low Pathogenic Avian Influenza virus H9N2, and Newcastle Disease Virus GVII (Whole virus).

ACTIVE INGREDIENTS

Full and balanced high concentration of inactivated:

Low Pathogenic Avian Influenza H9N2 (G Lineage)
Newcastle Disease Virus Genotype VII (Whole virus)
Newcastle Disease Virus Genotype II (Whole virus)

VACCINATION METHOD

Injection Subcutaneous or Intramuscular.

DOSE

0.2 ml / Bird



VALLEYVAC® Xceed H9N2

The Unique inactivated H9N2 vaccine especially designed for broiler flocks with full high concentration in 0.2 dose and empowered by immune stimulating complex for rapid and high level of protection for broiler flocks against Low Pathogenic Avian Influenza virus H9N2 (G Lineage).

ACTIVE INGREDIENTS

Full and balanced high concentration of inactivated:
Low Pathogenic Avian Influenza H9N2 G-Lineage

VACCINATION METHOD

Injection Subcutaneous or Intramuscular.

DOSE

0.2 ml / Bird



VALLEYVAC[®] Xceed ND^{G7}

The Unique inactivated ND^{G7} vaccine especially designed for broiler flocks with full high concentration in 0.2 dose and empowered by immune stimulating complex for wide, rapid and high level of protection for broiler flocks against Newcastle Disease Virus Genotype VII (Whole virus).

ACTIVE INGREDIENTS

Full and balanced high concentration of inactivated:

Newcastle Disease Virus Genotype VII (Whole virus)

Newcastle Disease Virus Genotype II (Whole virus)

VACCINATION METHOD

Injection Subcutaneous or Intramuscular.

DOSE

0.2 ml / Bird





Vaccine Valley

Existing Range

VALLEYVAC® 0.5 ml range

VALLEYVAC® H9-ND^{G7}



Inactivated bivalent vaccine of Low pathogenic avian influenza H9 (G Lineage) and Newcastle disease virus (NDV). For widest protection of poultry flocks through high antigenic mass of recent circulating LPAI H9N2 and Newcastle disease virus NDV.

INDICATION

Protection of poultry flocks against current circulating low pathogenic avian influenza H9N2 (G Lineage) and Newcastle disease virus GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated :
Low pathogenic avian influenza virus H9N2 G-Lineage
Newcastle Disease Virus GVII (Whole virus)
Newcastle Disease Virus GII (Whole Virus)




VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird



VALLEYVAC® AVIAN FLU H9N2



Inactivated low pathogenic avian influenza (LPAI) H9N2 for protection of poultry flocks through high antigenic mass of H9N2/ Dose.

INDICATION

Protection of poultry flocks against current circulating Low pathogenic avian influenza H9N2 (G Lineage).



ACTIVE INGREDIENTS

Balanced high concentration of inactivated:
Inactivated LPAI H9N2. (High Concentration)



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC® ND^{G7}



Inactivated Newcastle disease virus vaccine especially designed for high endemic areas with highest purified antigenic mass of NDV GVII Whole virus.

INDICATION

Protection of poultry flocks against Newcastle disease virus (NDV).

ACTIVE INGREDIENTS


Balanced High concentrations of Inactivated :
Newcastle Disease Virus GVII. (Whole virus)
Newcastle Disease Virus GII. (Whole Virus)

VACCINATION METHOD

Injection Subcutaneous or Intramuscular.

DOSE

0.5 ml / Bird.



VALLEYVAC® IBV3-H9N2



Inactivated vaccine of Infectious Bronchitis Virus (IBV) and Low pathogenic avian influenza H9N2 (G Lineage). For widest protection of poultry flocks through high antigenic mass of recent circulating IB Viruses (Classic, 2 variants serotypes) and LPAIV H9N2.

INDICATION

Protection of poultry flocks against current circulating Infectious Bronchitis Viruses and low pathogenic avian influenza viruses GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated:

IBV classic serotype.

IBV 2 variants serotypes.

Low pathogenic avian influenza virus H9N2 G-Lineage.




VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC® IBV3-ND^{G7}



Inactivated vaccine of Infectious Bronchitis Virus (IBV) and Newcastle disease virus (NDV). For widest protection of poultry flocks through high antigenic mass of recent circulating IB Viruses (Classic, 2 variants serotypes) and Newcastle disease virus NDV.

INDICATION

Protection of poultry flocks against current circulating Infectious Bronchitis Viruses and Newcastle disease virus GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated :

IBV classic serotype.

IBV 2 variants serotypes.

Newcastle Disease Virus GVII. (Whole virus)

Newcastle Disease Virus GII. (Whole Virus)




VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird



VALLEYVAC® IBV3-H9N2-ND^{G7}



Inactivated vaccine of Infectious Bronchitis Virus (IBV) and Low pathogenic avian influenza H9N2 (G Lineage) and Newcastle disease virus NDV. For widest protection of poultry flocks through high antigenic mass of recent circulating IB Viruses (Classic, 2 variants serotypes) and LPAIV H9N2 (G Lineage) and Newcastle disease virus GVII (Whole virus).

INDICATION

Protection of poultry flocks against current circulating Infectious Bronchitis Viruses, low pathogenic avian influenza viruses and Newcastle disease virus GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated:

IBV classic serotype.

IBV 2 variants serotypes.

Low pathogenic avian influenza virus H9N2 G Lineage.

Newcastle Disease Virus GVII. (Whole virus)

Newcastle Disease Virus GII. (Whole Virus)




VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC® Penta-Pro



Inactivated pentavalent vaccine for achieving widest protection to poultry flocks against recent circulating High pathogenic avian influenza viruses H5, low pathogenic avian influenza viruses H9 and Newcastle disease virus NDV.

INDICATION

Protection of poultry flocks against current circulating high pathogenic avian influenza viruses H5N8 & H5N1, low pathogenic avian influenza virus H9N2 (G Lineage) and Newcastle disease virus GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated:
 RG High pathogenic avian influenza clade 2.3.4.4b
 RG High pathogenic avian influenza clade 2.2.1.2
 Low pathogenic H9N2 G-Lineage
 Newcastle Disease Virus GVII (Whole virus)
 Newcastle Disease Virus GII (Whole virus)



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC® H5 PLUS ND^{G7}



Inactivated vaccine for achieving widest protection to poultry flocks against High pathogenic avian influenza viruses H5 and Newcastle disease virus NDV.

INDICATION

Protection of poultry flocks against current circulating high pathogenic avian influenza viruses H5N8 & H5N1, and Newcastle Disease Virus GVII (Whole virus).



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated :

RG High pathogenic avian influenza clade 2.3.4.4b

RG High pathogenic avian influenza clade 2.2.1.2

Newcastle Disease Virus GVII (Whole virus)

Newcastle Disease Virus GII (Whole virus)



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird



VALLEYVAC® AVIAN FLU H5 PLUS



Inactivated vaccine for achieving widest protection to poultry flocks against High pathogenic avian influenza viruses.

INDICATION

Protection of poultry flocks against current circulating high pathogenic avian influenza viruses H5N8 & H5N1.



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated:
RG High pathogenic avian influenza clade 2.3.4.4b
RG High pathogenic avian influenza clade 2.2.1.2



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird



VALLEYVAC® EDS-ND^{G7}



Inactivated vaccine of, Egg drop syndrome (EDS) and Newcastle disease virus NDV. For widest protection of poultry flocks through high antigenic mass of recent circulating EDS virus and Newcastle disease virus GVII (Whole virus).

INDICATION

Protection of poultry flocks against current circulating Egg drop syndrome virus and Newcastle disease virus GVII.

ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated :


Egg drop syndrome virus 76.
Newcastle Disease Virus GVII. (Whole virus)
Newcastle Disease Virus GII. (Whole Virus)

VACCINATION METHOD

Injection Subcutaneous or Intramuscular.

DOSE

0.5 ml / Bird.



VALLEYVAC® EDS-IBV3-ND^{G7}



Inactivated vaccine of Infectious Bronchitis Virus (IBV), Egg drop syndrome (EDS) and Newcastle disease virus NDV. For widest protection of poultry flocks through high antigenic mass of recent circulating IB Viruses (Classic, 2 variants serotypes) and EDS virus and Newcastle disease virus GVII (Whole virus).

INDICATION

Protection of poultry flocks against current circulating Infectious Bronchitis Viruses, Egg drop syndrome virus and Newcastle disease virus GVII.



ACTIVE INGREDIENTS

Balanced High concentrations of Inactivated:

IBV classic serotype.

IBV 2 variants serotypes.

Egg drop syndrome virus 76.

Newcastle Disease Virus GVII. (Whole virus)

Newcastle Disease Virus GII. (Whole Virus)




VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC® AdenoMax



Oil emulsion inactivated Fowl Adenovirus vaccine for protection of broilers, layers, and breeders against disease problems caused by infection with different serotypes of Fowl Adenovirus (FAdV) specially inclusion body hepatitis (IBH) and hydropericardium hepatitis syndrome (HHS).

INDICATION

Protection of broilers, layers, and breeders against disease problems caused by infection with different serotypes of Fowl Adenovirus (FAdV) specially inclusion body hepatitis (IBH) and hydropericardium hepatitis syndrome (HHS).



ACTIVE INGREDIENTS

Contains 3 strains of FAdVs:

Fowl Aviadenovirus D isolate.
Fowl Aviadenovirus E isolate.
Fowl Aviadenovirus E strain.



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.



VALLEYVAC[®] AdenoPro



An oil emulsion inactivated Fowl Adenovirus vaccine for protection of broilers, layers, and breeders against disease problems caused by infection with different serotypes of Fowl Adenovirus (FAdV) specially inclusion body hepatitis (IBH) and hydropericardium hepatitis syndrome (HHS).

INDICATION

Protection of broilers, layers, and breeders against disease problems caused by infection with different serotypes of Fowl Adenovirus (FAdV) specially inclusion body hepatitis (IBH) and hydropericardium hepatitis syndrome (HHS).



ACTIVE INGREDIENTS

Contains 3 strains of FAdVs:

Fowl Aviadenovirus D isolate.
Fowl Aviadenovirus C isolate.
Fowl Aviadenovirus E strain.



VACCINATION METHOD

Injection Subcutaneous or Intramuscular.



DOSE

0.5 ml / Bird.





Vaccine Valley

Duck Vaccines

VALLEYVAC[®] Duck vaccine range

VALLEYVAC® DERZSY



Oil emulsion inactivated vaccine of novel goose Parvo virus for Protection of ducks & geese flocks (either meat-type, layers or breeders) against derzsy disease

INDICATION

Protection of ducks & geese flocks against derzsy disease.



ACTIVE INGREDIENTS

Balanced high concentration of goose Parvo virus isolate.



VACCINATION METHOD

Vaccination Method: Injection subcutaneous or intramuscular.



DOSE

Duckling & Goslings: 0.2 ml / bird
Mature ducks & geese: 0.4 ml / bird



VALLEYVAC® Autogenous Solutions



Autogenous vaccines (custom-made vaccines)

Autogenous vaccines are made from field circulated strains that are not selected or optimized for the industrial propagation systems used for the vaccine manufacturing industry.


One serial can include either bacterial (bacterins) or viral antigens (viral autogenous vaccines). They have become an essential instrument in the production veterinarian's toolbox for the control of emerging and evolving diseases.

Autogenous vaccines have made significant advancements in the ability to reduce disease within the poultry industry from a combination of several different advancements in regulation requirements, rapid and accurate diagnostic assessments, and improvements in manufacturing.


The use of autogenous vaccines by poultry health professionals has also increased, and these custom-made products have been instrumental in combating diseases resulting from antigenic variants.



Vaccine Valley Soon pipeline ranges



- VALLEYVAC® Hatchery inactivated range
- VALLEYVAC® Live vaccines range
- VALLEYVAC® Recombinant vaccines range
- VALLEYVAC® Bacterines range




FMD

Always remember that

Vaccine Valley's main role is Protection not just Production
All ValleyVac® Range released under challenge in our lab. animals house to ensure highest efficacy in field.





Vaccine Valley Contacts



Eng. Ahmed Badawy
Chief Executive Officer



Mrs. Salma Badawy
Business Development Manager



Dr. Mohamed Adel
Commercial Director



Dr. Haitham El-massry
Business Unit Manager



Dr. Abdelrahman Shahin
Export Manager



Dr. Muhammed El-Naggar
Product Marketing Manager



f in 
vaccinevalley



 www.vaccinevalley.com

 info@vaccinevalley.com

 +2 38316772 | +2 38316773
+2 38316774 | +2 38316779

 101 extension of the sixth
industrial zone,
6th of October city, Egypt.